Vandana Abramson
Faculty Member
Last active: 3/27/2014

  1. A mechanically coupled reaction-diffusion model for predicting the response of breast tumors to neoadjuvant chemotherapy. Weis JA, Miga MI, Arlinghaus LR, Li X, Chakravarthy AB, Abramson V, Farley J, Yankeelov TE (2013) Phys Med Biol 58(17): 5851-66
    › Primary publication · 23920113 (PubMed) · PMC3791925 (PubMed Central)
  2. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Abramson VG, Grau AM, Gore JC, Yankeelov TE (2012) Magn Reson Med 68(1): 261-71
    › Primary publication · 22127821 (PubMed) · PMC3291742 (PubMed Central)
  3. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer. Abramson VG, Mayer IA (2012) Ther Adv Med Oncol 4(3): 139-47
    › Primary publication · 22590487 (PubMed) · PMC3349077 (PubMed Central)
  4. Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy. Abramson RG, Arlinghaus LR, Weis JA, Li X, Dula AN, Chekmenev EY, Smith SA, Miga MI, Abramson VG, Yankeelov TE (2012) Breast Cancer (Dove Med Press) 2012(4): 139-154
    › Primary publication · 23154619 (PubMed) · PMC3496377 (PubMed Central)
  5. An algorithm for longitudinal registration of PET/CT images acquired during neoadjuvant chemotherapy in breast cancer: preliminary results. Li X, Abramson RG, Arlinghaus LR, Chakravarthy AB, Abramson V, Mayer I, Farley J, Delbeke D, Yankeelov TE (2012) EJNMMI Res 2(1): 62
    › Primary publication · 23157877 (PubMed) · PMC3520720 (PubMed Central)
  6. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Abramson V, Arteaga CL (2011) Clin Cancer Res 17(5): 952-8
    › Primary publication · 21248299 (PubMed) · PMC3761872 (PubMed Central)
  7. Motion correction in diffusion-weighted MRI of the breast at 3T. Arlinghaus LR, Welch EB, Chakravarthy AB, Xu L, Farley JS, Abramson VG, Grau AM, Kelley MC, Mayer IA, Means-Powell JA, Meszoely IM, Gore JC, Yankeelov TE (2011) J Magn Reson Imaging 33(5): 1063-70
    › Primary publication · 21509862 (PubMed) · PMC3081111 (PubMed Central)
  8. Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer. Abramson VG, Mayer IA (2011) Curr Treat Options Oncol 12(4): 403-11
    › Primary publication · 21918859 (PubMed)
  9. A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer. Li X, Welch EB, Arlinghaus LR, Chakravarthy AB, Xu L, Farley J, Loveless ME, Mayer IA, Kelley MC, Meszoely IM, Means-Powell JA, Abramson VG, Grau AM, Gore JC, Yankeelov TE (2011) Phys Med Biol 56(17): 5753-69
    › Primary publication · 21841212 (PubMed) · PMC3176673 (PubMed Central)
  10. Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. Abramson VG, Troxel AB, Feldman M, Mies C, Wang Y, Sherman L, McNally S, Diehl A, Demichele A (2010) Anticancer Res 30(4): 1279-85
    › Primary publication · 20530440 (PubMed) · PMC3874215 (PubMed Central)